Our finding suggests that SAF could be useful in selecting T2D patients in whom the screening for CAD by means of CACs assessment would be more cost-effective (Acta Diabetologica)
Diabetes News
Tag: Type 2 Diabetes
Gut microbiota changes after metabolic surgery in adult diabetic patients with mild obesity: a randomised controlled trial
This was the first RCT studying composite clinical, analytic, and microbiome changes in T2DM patients with class 1 obesity after RYGB versus standard medical therapy. The remarkable phenotypic improvement after surgery occurred concomitantly with changes in the gut microbiome, but at a lower level (Diabetology & Metabolic Syndrome)
Metabolic surgery for type II diabetes: an update
High quality data from RCTs have clearly established that bariatric procedures are more effective than medical or lifestyle interventions for inducing weight loss and remission of type 2 diabetes, even in mild obese patients with a BMI between 30 and 35 kg/m2 (Acta Diabetologica)
Ethnicity-specific BMI cutoffs for obesity based on type 2 diabetes risk in England: a population-based cohort study
We aimed to prospectively identify ethnicity-specific BMI cutoffs for obesity based on the risk of type 2 diabetes that are risk-equivalent to the BMI cutoff for obesity among White populations (≥30 kg/m2). (Lancet)
SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline
What are the benefits and harms of sodium-glucose cotransporter 2 (SGLT-2) inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists when added to usual care (lifestyle interventions and/or other diabetes drugs) in adults with type 2 diabetes at different risk for cardiovascular and kidney outcomes? (BMJ)
Lower Risk of Hospitalisation for Heart Failure, Kidney Disease and Death with Sodium Glucose Co‐Transporter‐2 Compared to Dipeptidyl Peptidase‐4 Inhibitors in Type 2 Diabetes Regardless of Prior Cardiovascular or Kidney Disease
SGLT2i were associated with reduced risk of all–cause mortality and hospitalisation for HF and CKD compared with DPP4–i, highlighting the need to introduce SGLT2i early in the management of T2D patients (Diabetes, Obesity and Metabolism)
Sex differences in the association of prediabetes and type 2 diabetes with microvascular complications and function: The Maastricht Study
Our findings show that women with type 2 diabetes are not disproportionately affected by early microvascular complications (Cardiovascular Diabetology)
The association of amputations and peripheral artery disease in patients with type 2 diabetes mellitus receiving sodium-glucose cotransporter type-2 inhibitors: real-world study
The risk of amputation in patients treated with SGLT-2i and incretins was not higher compared with other ADDs. Pre-existing PAD was the greatest driver of amputation risk (European Heart Journal)
The relationship between gut microbiota, short-chain fatty acids and type 2 diabetes mellitus: the possible role of dietary fibre
increasing daily fibre intake in the context of a healthy dietary pattern might be a valid tool to improve microbiota composition and activity to prevent metabolic diseases (Acta Diabetologica)
Short‐term Intensive Insulin as Induction and Maintenance Therapy for the Preservation of Beta‐cell Function in early Type 2 Diabetes (RESET IT): A 2‐year Randomized Controlled Trial
Although initial induction IIT induces metabolic improvement, subsequent repeat courses of IIT every 3‐months do not further enhance the effect of metformin maintenance therapy on beta‐cell function (Diabetes, Obesity and Metabolism)
Reduced beta cell number rather than size is a major contributor to beta cell loss in type 2 diabetes
Both beta cell size and number were reduced in participants with type 2 diabetes, with the relative reduction in beta cell number being greater. Decrease in beta cell number appears to be a major contributor to reduced BCM in type 2 diabetes (Diabetologia)
Associations between attainment of incentivized primary care indicators and incident lower limb amputation among those with type 2 diabetes: a population-based historical cohort study
Comprehensive primary care-based secondary prevention may offer considerable protection against diabetes-related amputation. This has important implications for diabetes management and medical decision-making for patients, as well as type 2 diabetes quality improvement programs (BMJ Open, Diabetes Research & Care)
One Year of Dapaglifozin Add-On Therapy Ameliorates Surrogate Indexes of Insulin Resistance and Adiposity in Patients with Type 2 Diabetes Mellitus
Dapagliflozin treatment significantly reduced surrogate indexes of insulin resistance and adiposity in patients with T2D (Diabetes Therapy)
Importance of Early Screening and Diagnosis of Chronic Kidney Disease in Patients with Type 2 Diabetes
Medications shown to slow progression of CKD include renin–angiotensin system inhibitors, sodium–glucose cotransporter-2 inhibitors, glucagon-like peptide 1 receptor agonists and, more recently, non-steroidal mineralocorticoid receptor antagonists (Diabetes Therapy)
Association of Insulin Glargine Treatment with Bone Mineral Density in Patients with Type 2 Diabetes Mellitus
These results suggest that insulin glargine may affect bone metabolism in patients diagnosed with T2DM. The study has implications for the selection of hypoglycemic agents for diabetic patients at risk of osteoporosis (Diabetes, Metabolic Syndrome and Obesity)
From glucose lowering agents to disease/diabetes modifying drugs: a “SIMPLE” approach for the treatment of type 2 diabetes
Early combination therapy with two and sometimes three of the DMDs (SGLT2i and GLP-1 RA) and metformin, and lower HbA1c targets (< 6.5%), may halt and even regress the pathological basis of diabetes and improve patient’s prognosis (Cardiovascular Diabetology)
Significant abnormal glycemic variability increased the risk for arrhythmias in elderly type 2 diabetic patients
The study demonstrated the elderly patients had greater glycemic variability and were more prone to arrhythmias. Therefore, active control of blood glucose fluctuation in elderly patients will help to reduce the risk of severe arrhythmia (BMC Endocrine Disorders)
Association of Glycated Albumin/Glycosylated Hemoglobin Ratio with Blood Glucose Fluctuation and Long-Term Blood Glucose Control in Patients with Type 2 Diabetes Mellitus
The GA/HbA1c ratio is closely related to the MAGE and islet function in patients with T2DM (Diabetes, Metabolic Syndrome and Obesity)
Association of genetic variants for plasma LRG1 with rapid decline in kidney function in patients with type 2 diabetes
We demonstrate that genetically influenced plasma LRG1 increases the risk of RDKF in T2D patients suggesting plasma LRG1 as a potential treatment target. However, further studies are warranted to elucidate underlying pathways to provide insight into DKD prevention (Journal of Clinical Endocrinology & Metabolism)
All Wales Advice on SGLT-2 Inhibitors in Type 2 Diabetes and Cardiovascular Disease
Consultation
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 56
- Next Page »
Glycosmedia is also available as an App: